CHICAGO, IL—The use of botulinum toxin type A in patients undergoing cardiac surgery does not seem to reduce the rate of postoperative atrial fibrillation (AF) overall, according to the phase II NOVA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback